BridgeBio Pharma Inc. published a document on the CLARIFY disease monitoring study, which is a global, multicenter, longitudinal, non-interventional study. The study aims to understand the disease burden, management, and progression in pediatric and adult participants with Autosomal Dominant Hypocalcemia Types 1 and 2 (ADH1/2) over five years. The document includes details on the study design, methods, and baseline characteristics of pediatric participants. The full document can be accessed through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。